Mark Currie Net Worth

The estimated Net Worth of Mark G Currie is at least $12.8 Million dollars as of 11 August 2022. Mark Currie owns over 70,000 units of Ironwood Pharmaceuticals Inc stock worth over $2,269,647 and over the last 15 years he sold IRWD stock worth over $6,349,355. In addition, he makes $4,132,130 as Director at Ironwood Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Currie IRWD stock SEC Form 4 insiders trading

Mark has made over 36 trades of the Ironwood Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 70,000 units of IRWD stock worth $824,600 on 11 August 2022.

The largest trade he's ever made was exercising 300,000 units of Ironwood Pharmaceuticals Inc stock on 31 October 2016 worth over $882,000. On average, Mark trades about 43,839 units every 70 days since 2010. As of 11 August 2022 he still owns at least 521,758 units of Ironwood Pharmaceuticals Inc stock.

You can see the complete history of Mark Currie stock trades at the bottom of the page.

Mark Currie biography

Dr. Mark G. Currie, Ph.D. is Director of the Company. Dr. Currie has served as president and chief scientific officer of Cyclerion Therapeutics, Inc. since April 2019, and previously served as senior vice president, chief scientific officer and president of R&D at Ironwood Pharmaceuticals, Inc. from 2002 to April 2019.Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc. Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University. Currie's vast experience leading the research and development efforts of an international biotechnology company will prove instrumental in guiding us through the research and development of novel therapie

What is the salary of Mark Currie?

As the Director of Ironwood Pharmaceuticals Inc, the total compensation of Mark Currie at Ironwood Pharmaceuticals Inc is $4,132,130. There are 2 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of $10,068,800.

How old is Mark Currie?

Mark Currie is 65, he's been the Director of Ironwood Pharmaceuticals Inc since 2019. There are 2 older and 17 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.

What's Mark Currie's mailing address?

Mark's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.

Insiders trading at Ironwood Pharmaceuticals Inc

Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts und Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.

What does Ironwood Pharmaceuticals Inc do?

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Complete history of Mark Currie stock trades at Ironwood Pharmaceuticals Inc und Cyclerion Therapeutics

Ironwood Pharmaceuticals Inc executives and stock owners

Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Mallon,
  Chief Executive Officer, Director
• Thomas McCourt,
  President
• Mark Currie,
  Director
• Gina Consylman,
  Chief Financial Officer, Senior Vice President
• Thomas A. McCourt,
  CEO & Director
• Jason Rickard,
  COO & Sr. VP of Operations
• Dr. Michael Shetzline M.D., Ph.D.,
  Chief Medical Officer, Sr. VP and Head of R&D
• Catherine Moukheibir,
  Independent Director
• Jon Duane,
  Independent Director
• Marla Kessler,
  Independent Director
• Julie McHugh,
  Independent Chairman of the Board
• Andrew Dreyfus,
  Independent Director
• Edward Owens,
  Independent Director
• Lawrence Olanoff,
  Independent Director
• Julie H. McHugh,
  Exec. Chairman
• Alexander Denner,
  Director
• Meredith Kaya,
  Vice President - Investor Relations and Corporate Communications
• Michael Shetzline,
  Chief Medical Officer, Senior Vice President and Head of Drug Development
• Conor Kilroy,
  Senior Vice President, General Counsel
• Jason Rickard,
  Chief Operating Officer, Senior Vice President
• John Minardo,
  Sr. VP & Chief Legal Officer
• Marcel Moulaison,
  VP of Technical Operations
• Ronald Silver,
  Corp. Controller & Principal Accounting Officer
• Sravan Kumar Emany,
  Sr. VP & CFO
• G. Todd Milne,
  Co-Founder and VP of sGC R&D
• Brian M. Cali,
  Co-Founder and Sr. VP of R&D Strategy & External Innovation
• Terrance Mcguire,
  Director
• Douglas E Williams,
  Director
• Amy W Schulman,
  Director
• Marsha Fanucci,
  Director
• Christopher T Phd Walsh,
  Director
• Peter M Hecht,
  Chief Executive Officer
• Thomas Graney,
  Chief Financial Officer
• William Huyett,
  Chief Operating Officer
• Halley E Gilbert,
  Chief Admin Officer & SVP
• Bryan E Roberts,
  Director
• Associatesvenrock Associate...,
  
• Management Llc Vr,
  10% owner
• Llc Fmr,
  10% owner
• Llcfil Ltd Fmr,
  
• Co Investment Holdings, Llc...,
  
• Capital Investments L.P.Rid...,
  
• Joseph C Jr Cook,
  Director
• George H Conrades,
  Director
• David Evans Shaw,
  Director
• David A Ebersman,
  Director
• Michael J Higgins,
  Chief Operating Officer
• Kelly Mac Donald,
  Chief Accounting Officer
• Jay Shepard,
  
• Sravan Kumar Emany,
  SVP, Chief Financial Officer
• Alexander J Sarissa Capital...,
  
• Andrew Davis,
  SVP, Chief Business Officer
• Ronald Silver,
  Principal Accounting Officer
• Minardo John,
  Chief Legal Officer